Springer Nature
Browse
40780_2018_128_MOESM1_ESM.pptx (83.66 kB)

Additional file 1: of Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

Download (83.66 kB)
presentation
posted on 2018-12-10, 05:00 authored by Hisanori Shimizu, Kenichi Suzuki, Takeshi Uchikura, Daiki Tsuji, Takeharu Yamanaka, Hironobu Hashimoto, Koichi Goto, Reiko Matsui, Nobuhiko Seki, Toshikazu Shimada, Shunya Ikeda, Naoki Ikegami, Toshihiro Hama, Nobuyuki Yamamoto, Tadanori Sasaki
Figure S1. The structure of the category and effect measurement of CINV. The CR rates in the TRIPLE study were 59.1% (244/413 patients) for the GRA group and 65.7% (272/414 patients) for the PALO group. Regarding the case of CR or non-CR, we devised three categories according to the development of overall CINV as well as acute and delayed CINV (category 1, CR [0–120 h]; category 2, non-CR delayed; category 3, non-CR acute). (PPTX 83 kb)

History